SCHEMBL92347

SCHEMBL92347

CO[C@H]1CNC[C@@H]1OC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1838472 1.00
SCHEMBL266763 1.00
SCHEMBL10273863 1.00
SCHEMBL2242257 1.00
Hydrochloric Acid SCHEMBL25361523 0.97 CCR5 (0.33)
Hydrochloric Acid SCHEMBL3207412 0.97 CCR5 (0.33)
Hydrochloric Acid SCHEMBL3852859 0.97 CCR5 (0.33)
Hydrochloric Acid SCHEMBL74538 0.97 CCR5 (0.33)
SCHEMBL8204795 0.84 CCR5 (0.30)
SCHEMBL14290221 0.82

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240270740-A1 INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF VENTUS THERAPEUTICS U.S., INC. 2024-08-15 US disclosed
WO-2017088755-A1 AMINOPYRIMIDINE HETEROCYCLIC COMPOUND WITH ADENOSINE RECEPTOR ANTAGONISTIC ACTIVITY Suzhou Yunxuan Yiyao Keji Youxian Gongsi (CN) 2017-06-01 WO disclosed
US-20130065882-A1 VLA-4 inhibitory drug MACHINAGA NOBUO (JP) 2013-03-14 US disclosed
US-20120157437-A1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-06-21 US disclosed
US-8129366-B2 VLA-4 inhibitory drug DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-03-06 US disclosed
US-20090233901-A1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-17 US disclosed
US-7091198-B1 2,5-disubstituted pyrimidine derivatives BAYER HEALTHCARE AG (DE) 2006-08-15 US disclosed
US-20060167016-A1 2,5-DISUBSTITUTED PYRIMIDINE DERIVATIVES BAYER HEALTHCARE AG (DE) 2006-07-27 US disclosed
EP-1525202-B1 NOVEL 2,5-DISUBSTITUTED PYRIMIDINE DERIVATIVES BAYER HEALTHCARE AG (DE) 2006-01-11 EP disclosed
EP-1525202-A1 NOVEL 2,5-DISUBSTITUTED PYRIMIDINE DERIVATIVES Bayer HealthCare AG (DE) 2005-04-27 EP disclosed
US-6833456-B2 Heterocyclic sulfides such as 5-(2-(2R-Hydroxymethyl-pyrrolidine-1-carbonyl)-thieno(3,2-b)pyridin-7 -ylamino)-2-methyl-indole-1-carboxylic acid methylamide, used as angiogenesis inhibitors AGOURON PHARMACEUTICALS, INC. 2004-12-21 US disclosed
EP-1483268-A2 INDOLYL-UREA DERIVATIVES OF THIENOPYRIDINES USEFUL AS ANTI-ANGIOGENIC AGENTS PFIZER INC. (US) 2004-12-08 EP disclosed
WO-2004009589-A1 NOVEL 2,5-DISUBSTITUTED PYRIMIDINE DERIVATIVES BAYER HEALTHCARE AG (DE) 2004-01-29 WO disclosed
US-20040019065-A1 Indolyl-urea derivatives of thienopyridines useful as antiangiogenic agents, and methods for their use ROMINES WILLIAM HENRY (US) 2004-01-29 US disclosed
WO-2003074529-A2 iNDOLYL-UREA DERIVATIVES OF THIENOPYRIDINES USEFUL AS ANTI-ANGIOGENIC AGENTS PFIZER INC. (US) 2003-09-12 WO disclosed